Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-Meldung: Gleich zu Wochenbeginn prozentual dreistellig? Der frühe Vogel…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1KAVV | ISIN: IE00B91XRN20 | Ticker-Symbol: 0PT
Tradegate
27.03.25
18:13 Uhr
12,000 Euro
-0,100
-0,83 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
PROTHENA CORPORATION PLC Chart 1 Jahr
5-Tage-Chart
PROTHENA CORPORATION PLC 5-Tage-Chart
RealtimeGeldBriefZeit
11,90012,20030.03.
12,00012,10028.03.

Aktuelle News zur PROTHENA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoProthena (NASDAQ:PRTA) Trading 4.8% Higher - Should You Buy?1
27.02.PROTHENA CORP PUBLIC LTD CO - 10-K, Annual Report1
24.02.Prothena Corp Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)5
PROTHENA Aktie jetzt für 0€ handeln
21.02.Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus2
21.02.Prothena outlines potential multi-billion dollar opportunity with birtamimab launch by 20261
20.02.Prothena GAAP EPS of -$1.08 misses by $0.04, revenue of $2.12M misses by $5.41M2
20.02.Prothena Corporation plc: Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights302Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2...
► Artikel lesen
20.02.PROTHENA CORP PUBLIC LTD CO - 8-K, Current Report3
13.02.Prothena Corporation plc: Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025296Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
► Artikel lesen
07.02.Deep Dive Into Prothena Corp Stock: Analyst Perspectives (5 Ratings)3
30.12.24Prothena Corporation plc: Prothena Announces Board of Directors Update424Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
► Artikel lesen
30.12.24PROTHENA CORP PUBLIC LTD CO - 8-K, Current Report-
20.12.24Demystifying Prothena Corp: Insights From 6 Analyst Reviews1
19.12.24Prothena-Aktie steigt trotz verfehltem Studienziel12
19.12.24Prothena stock soars despite study miss1
19.12.24Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease2
19.12.24Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits5
19.12.24Roche, Prothena miss main goal in mid-stage trial for Parkinson's drug8
19.12.24Roche reports failure of Prothena-partnered Parkinson's prospect in phase 2b, but highlights positives12
19.12.24Prothena Corporation plc: Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease540PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints Prasinezumab continues to be well tolerated and no new safety...
► Artikel lesen
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1